Aptinyx Reaches Milestones, Raises $70m To Develop NMDA Modulators

Aptinyx – spun out of Naurex in 2015 after it was acquired by Allergan – closed a Series B venture capital round that brought in new investors with a long-term view, the ability to support a future IPO and experience with neuroscience drugs.